Development of siRNA lipoplexes for intracellular delivery in lung cancer cells
1Department of Pharmacy, Faculty of Technology and Engineering, The Maharaja Sayajirao University of Baroda, Kalabhavan, Vadodara, Gujarat, India.
Abstract:
Lung cancer occurrence throughout the world and its unsatisfactory treatment has drawn significant attention from many medical agencies. A genomic approach utilizing siRNA against target gene may resolve this problem. Present investigation includes siRNA lipoplex formulation and its in-vitro characterisation in lung cancer cell line for intracellular uptake and cytotoxicity. Accumulation of siRNA inside the cell as well as less cytotoxicity of prepared carrier system signifies potential of prepared siRNA lipoplex in the treatment of lung cancer.
Insights
This study developed a novel siRNA lipoplex carrier for lung cancer treatment. The formulation showed promising intracellular uptake and low cytotoxicity in lung cancer cells, indicating its therapeutic potential.
Area of Science:
- Biotechnology
- Genomics
- Cancer Research
Background:
- Lung cancer presents a global health challenge with limited effective treatments.
- Genomic approaches, such as small interfering RNA (siRNA), offer potential therapeutic strategies.
- Targeting specific genes with siRNA requires effective delivery systems.
Purpose of the Study:
- To formulate and characterize siRNA lipoplex for lung cancer therapy.
- To evaluate the in vitro intracellular uptake of the siRNA lipoplex in lung cancer cells.
- To assess the cytotoxicity of the developed carrier system.
Main Methods:
- Formulation of siRNA lipoplex nanoparticles.
- In vitro characterization of lipoplex in a lung cancer cell line.
- Assessment of intracellular siRNA accumulation.
- Evaluation of cytotoxicity assays.
Main Results:
- Successful formulation of siRNA lipoplex.
- Significant intracellular accumulation of siRNA within lung cancer cells.
- Demonstrated low cytotoxicity of the lipoplex carrier system.
Conclusions:
- The developed siRNA lipoplex carrier shows potential for lung cancer treatment.
- Effective intracellular delivery and minimal toxicity highlight its therapeutic promise.
- Further in vivo studies are warranted to validate its efficacy.
Related Concept Videos
02:15Experimental RNAi
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...